Superficial thrombophlebitisMANAGEMENT

CARDIOVASCULAR PRESENTATIONS · 12 SECTIONS

⚲

299 items

☷ Legend

01Approach to the Critical Patient/attcp21

Triage and immediate risks

›Immediate priorities

›Hemodynamic instability

›Alternative diagnosis or complication

›Systemic toxicity

›Suppurative thrombophlebitis concern

›Respiratory symptoms

›Concomitant pulmonary embolism concern

›Limb threat

›Phlegmasia or arterial compromise alternative concern

Key concepts

›Core concept

›Superficial venous thrombosis with local inflammation

›Risk of extension into deep system

›Concomitant deep vein thrombosis possibility

›High risk anatomy

›Great saphenous vein within 3 cm of saphenofemoral junction

›Small saphenous vein near saphenopopliteal junction

Immediate actions and escalation triggers

›Escalation triggers

›If hypotension or syncope, PE pathway and resuscitation bay

›If high suspicion, anticoagulation per PE protocol unless contraindicated

›If fever with purulence or indwelling catheter and bacteremia concern, broad spectrum antibiotics and source control

›If septic, sepsis pathway and admission

02History/hx31

Symptoms and timeline

›Symptom profile

›Localized pain along superficial vein

›Cord like tenderness

›Erythema and warmth distribution

›Linear tracking pattern

›Onset time

›Days to weeks course

›Progression

›Proximal spread along vein

Risk factors and provoking factors

›Thrombosis risks

›Recent surgery or trauma

›Immobilization

›Pregnancy or postpartum

›Estrogen exposure

›Prior venous thromboembolism

›Known thrombophilia

›Active cancer

›Recent chemotherapy

›Varicose veins

›Recurrent superficial thrombosis

›Central or peripheral venous catheter

›Upper extremity superficial thrombosis

Red flags and alternate etiologies

›Complication signals

›Dyspnea

›Pleuritic chest pain

03Physical Exam/exam20

Local examination

›Local findings

›Palpable tender cord

›Segment length estimation

›Overlying erythema

›Borders and proximal extent marking

›Warmth and edema

›Disproportionate swelling concern for DVT

Limb and systemic assessment

›Associated findings

›Calf circumference asymmetry

›Pitting edema

›Distal pulses and perfusion

›Alternative arterial pathology if abnormal

›Vital signs

›Fever

›Tachycardia

PITFALLS

›Common pitfalls

›Cellulitis misdiagnosis

›Lack of palpable cord does not exclude SVT

›Underestimating proximal extension

›Junction proximity missed without ultrasound

04Differential Diagnosis/ddx27

Life threatening and must not miss

›Critical differentials

›Deep vein thrombosis

›ICD-10 I82 series

›Pulmonary embolism

›ICD-10 I26 series

›Suppurative thrombophlebitis

›Bacteremia risk with catheter associated thrombosis

Common mimics

›Mimics

›Cellulitis

›ICD-10 L03 series

›Lymphangitis

›Linear erythema without venous cord

›Superficial venous insufficiency flare

›Varicosities with pain

›Erythema nodosum

›Tender nodules not cord like

›Ruptured Baker cyst

›Posterior calf pain and swelling

Coding and terminology

›Coding anchors

›ICD-10 I80.0

›Superficial thrombophlebitis of lower extremities

›ICD-10 I80.8

›Superficial thrombophlebitis of other sites

›ICD-10 I80.9

›Phlebitis and thrombophlebitis unspecified

05Laboratory Tests/lt20

When labs are needed

›Lab indications

›Systemic symptoms

›Infection evaluation

›Anticoagulation planned

›Baseline bleeding risk assessment

›Recurrent or unprovoked events

›Malignancy screen consideration guided by history

Suggested tests by scenario

›Targeted tests

›Complete blood count for fever or toxicity

›Leukocytosis support for infection

›Creatinine and electrolytes for anticoagulant selection

›Renal function for fondaparinux or DOAC use

›Liver enzymes for DOAC selection considerations

›Significant hepatic disease contraindication pattern

›Coagulation studies when bleeding risk unclear or liver disease

›INR and aPTT baseline

PITFALLS and limits

›Lab limitations

›D dimer

›Not specific for SVT

›Not reliable to exclude concomitant DVT in higher risk presentations

06Diagnostic Tests/dt32

Scoring Systems

›Decision support

›Wells score for DVT when concern for concomitant DVT

›Higher pretest probability pathway

›Lower pretest probability pathway

›PE probability tools when symptoms suggest PE

›Structured risk assessment before imaging

MRI

›MRI role

›Rare indications

›Pelvic or proximal venous disease clarification when ultrasound limited

›Limits

›Not first line for typical extremity SVT

›CT role

›PE protocol CT pulmonary angiography for PE concern

›Triggered by symptoms and risk assessment

›Contrast CT for septic thrombophlebitis complications when deep extension suspected

›Abscess or deep space infection concern

Ultrasound

›Duplex ultrasound

›Diagnostic goals

›SVT confirmation

›Length measurement

›Distance to saphenofemoral or saphenopopliteal junction

›DVT exclusion

›Deep system compressibility assessment

›Indications for ultrasound

07Disposition/dispo16

Outpatient versus admission

›Disposition criteria

›Outpatient typical

›Stable vitals

›No PE symptoms

›No suppurative features

›Admission triggers

›Suspected PE or confirmed DVT

›Suppurative thrombophlebitis concern

›Severe pain uncontrolled with oral therapy

›High bleeding risk with need for close monitoring

Follow up and safety net

›Follow up plan

›Primary care or thrombosis clinic within 3 to 7 days

›Earlier if progression

›Repeat ultrasound plan

›If symptoms progress despite therapy

›If near junction and treated conservatively

08Treatment/t58

Nonpharmacologic measures

›Supportive care

›Ambulation as tolerated

›Avoid prolonged immobility

›Compression stockings if tolerated

›Symptom relief and edema reduction

›Warm or cool compresses based on comfort

›Local symptom control

Analgesia and anti inflammatory therapy

›Symptom control medications

›NSAID options

›Ibuprofen PO 400 mg every 6 to 8 hours as needed

›Maximum 2400 mg per day typical outpatient limit

›Naproxen PO 250 to 500 mg twice daily as needed

›Gastroprotection if high GI risk

›Acetaminophen

›Acetaminophen PO 500 to 1000 mg every 6 to 8 hours as needed

›Maximum 3000 mg per day in many outpatient settings

Anticoagulation indications and regimens

›Anticoagulation decision

›Indications for anticoagulation

›Segment length 5 cm or longer

›Lower extremity SVT typical threshold used in trials and guidelines

›Proximity to saphenofemoral junction within 3 cm

›Treat as DVT strategy in many protocols

›Severe symptoms

›Functional limitation

›Greater saphenous involvement above knee

09Special Populations/sp24

Pregnancy

›Pregnancy considerations

›Higher baseline VTE risk

›Lower threshold for ultrasound evaluation

›Anticoagulant selection

›Low molecular weight heparin preferred when anticoagulation indicated

›Weight based dosing per pregnancy thrombosis protocol

›Medication cautions

›Avoid NSAIDs in later pregnancy if possible

›Avoid DOACs in pregnancy

Geriatric

›Older adult considerations

›Higher bleeding risk

›Anticoagulation risk benefit review

›Renal function decline

›Dose adjustments for fondaparinux and LMWH

›Polypharmacy

›Drug interaction screen for DOACs and NSAIDs

Pediatrics

›Pediatric considerations

›SVT uncommon

›Catheter associated cases more common

›Ultrasound guidance

›Confirm diagnosis and exclude deep extension

›Anticoagulation decisions

›Hematology consultation typical

›Weight based LMWH protocols when indicated

10Background/b19

Epidemiology

›Epidemiology overview

›Common association with varicose veins in lower extremity

›Recurrent episodes possible

›Clinically important overlap with DVT

›Concomitant DVT risk present in a minority of cases

Pathophysiology

›Mechanism

›Thrombus formation in superficial vein

›Local inflammatory response in vessel wall

›Extension pathways

›Propagation toward deep venous junctions

›Embolization risk primarily when deep extension occurs

Therapeutic Considerations

›Therapy rationale

›NSAIDs

›Reduce local inflammation and pain

›Anticoagulation in higher risk SVT

›Reduce extension to DVT or PE

›Typical duration 45 days for isolated extensive SVT based on trial designs

›Compression and mobilization

›Symptom improvement and venous return support

11Patient Discharge Instructions/pdi22

copy discharge instructions

›Discharge bundle

›Diagnosis explanation

›Clot and inflammation in a surface vein

›Home care

›Walk regularly and avoid prolonged sitting

›Compression stockings if advised

›Compresses for comfort

›Medications

›NSAID use only as directed

›If on anticoagulant, strict daily adherence

›Return to ED immediately

›Shortness of breath

›Chest pain

›Coughing blood

›Fainting

›Rapidly increasing leg swelling

›Spreading redness or severe pain

›Fever or shaking chills

›Any major bleeding

›Follow up

›Recheck within 3 to 7 days

›Earlier if symptoms spreading up the leg

12References/r9

Guidelines and key evidence

›Core references

›CHEST guideline on antithrombotic therapy for VTE disease

›Recommendations for superficial venous thrombosis anticoagulation in higher risk cases

›CALISTO trial

›Fondaparinux 2.5 mg daily for 45 days reduced VTE complications in SVT

›SURPRISE trial

›Rivaroxaban 10 mg daily compared with fondaparinux for SVT in selected patients

›Society for Vascular Surgery and venous disease guidance statements

›Imaging and management principles for SVT and junction proximity

Learn More: Superficial thrombophlebitis→

Comprehensive Clinical Review

Structured, evidence-informed, long-form analysis for deeper understanding.

Evidence & Review

Reviewed by SymptomDx Medical Team · Last reviewed August 18, 2026

SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.